• 1
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 70514.
  • 2
    Rustgi VK. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007; 42: 51321.
  • 3
    Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL. Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 2005; 42: 140613.
  • 4
    Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 22742.
  • 5
    Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 57987.
  • 6
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 7
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 8
    Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2007; 25: 115362.
  • 9
    Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 244451.
  • 10
    Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 242941.
  • 11
    Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 48391.
  • 12
    Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 2808.
  • 13
    Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33: 23140.
  • 14
    Cummings KJ, Lee SM, West ES, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA 2001; 285: 1939.
  • 15
    Davis GL. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Semin Liver Dis 1999; 19(Suppl. 1): 4955.
  • 16
    Shiffman ML, Hofmann CM, Sterling RK, Luketic VA, Contos MJ, Sanyal AJ. A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response. J Infect Dis 2001; 184: 4059.
  • 17
    Kwo P, Lawitz EJ, McCone J. High Sustained Virologic Response (SVR) in Genotype 1 (GI) Null Responders to PEG-Interferon alfa-2B (P) plus Ribavirin (R) when treated with Boceprevir (BOC) combination therapy. Hepatology 2009; 4: 331A.
  • 18
    McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 182738.
  • 19
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 133574.
  • 20
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 112.
  • 21
    Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 153958.
  • 22
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 55760.
  • 23
    Copas JB, Shi JQ. A sensitivity analysis for publication bias in systematic reviews. Stat Methods Med Res 2001; 10: 25165.
  • 24
    Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001; 20: 64154.
  • 25
    Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 161828.
  • 26
    Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009; 49: 183846.
  • 27
    Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med 2009; 150: 52840.
  • 28
    Bergmann JF, Vrolijk JM, Van der Schaar P, Vroom B, Van Hoek B. Gamma-glutamyltransferase and rapid virologic response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. Liver Int 2007; 27: 121725.
  • 29
    Diago M, Crespo J, Olveira A, et al. Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients. Aliment Pharmacol Ther 2007; 26: 11318.
  • 30
    Dollinger MM, Dridi Y, Lesske J, Behl S, Fleig WE. Efficacy of daily consensus interferon and ribavirin compared to PEG-interferon alfa-2b and ribavirin in non-responders with chronic hepatitis C. Hepatology 2005; 42: 691A.
  • 31
    Gross J, Johnson S, Kwo P, Afdhal N, Flamm S, Therneau T. Double dose peginterferon alfa-2b with weight-based ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: final results of “RENEW”. Hepatology 2005; 42: 219A.
  • 32
    Jacobson IM, Gonzalez SA, Ahmed F, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100: 245362.
    Direct Link:
  • 33
    Lawitz EJ, Bala NS, Becker S, Brown G, Davis M, Dhar R. Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy. Gastroenterology 2003; 124: 783A.
  • 34
    Scotto G, Fazio V, Fornabaio C, et al. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study. J Interferon Cytokine Res 2008; 28: 6239.
  • 35
    Kaiser S, Lutze B, Sauter B, Bissinger L, Werner C. Retreatment of HCV genotype 1 relapse patients to peginterferon/ribavirin therapy with an extended treatment regimen of 72 weeks with consensus interferon/ribavirin versus peginterferon alpha/ribavirin. Hepatology 2007; 46: 819A.
  • 36
    Nevens F, Van Vlierberghe H, D’heygere F, Delwaide J, Adler M, Henrion J. Peginterferon alfa-2a (40kDa) plus ribavirin is as effective in patients relapsing after conventional interferon based therapy as in naive patients: results from the BERNAR-1 trial. J Hepatol 2005; 42: 214.
  • 37
    Cheinquer H, Pessoa M, Almeida P, Silva G, Patelli M. Prospective randomized study of peginterferon alpha-2a, ribavirin and amantadine vs peginterferon alpha-2a plus ribavirin, in hepatitis C patients now responders or relapsers to interferon-alpha and ribavirin. J Hepatol 2006; 44: S209.
  • 38
    Ciancio A, Picciotto A, Giordanino C, et al. A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. Aliment Pharmacol Ther 2006; 24: 107986.
  • 39
    Fargion S, Borzio M, Maraschi A, Cargnel A. Triple antiviral therapy in HCV positive patients who failed prior combination therapy. World J Gastroenterol 2006; 12: 5293300.
  • 40
    Hasan F, Al-Khaldi J, Asker H, et al. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin. Antivir Ther 2004; 9: 499503.
  • 41
    Herrine SK, Brown RS Jr, Bernstein DE, Ondovik MS, Lentz E, Te H. Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety. Dig Dis Sci 2005; 50: 71926.
  • 42
    Mangia A, Cimino L, Persico M, Demelia L, Rumi M, Spinzi G. Enhanced response to peginteferon alfa2a-based triple therapy in previously non-responsive chronic hepatitis C: final results of PRETTY study. J Hepatol 2005; 42: 2001.
  • 43
    Mangia A, Ricci GL, Persico M, et al. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. J Viral Hepat 2005; 12: 2929.
  • 44
    Maynard M, Pradat P, Bailly F, et al. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). J Hepatol 2006; 44: 48490.
  • 45
    Jensen D, Marcellin P. Reply to Treatment of Nonresponder Patients with Chronic Hepatitis C: To Repeat or Not to Repeat? That is the Question. Gastroenterology 2009; 137: 1524.
  • 46
    Hezode C, Foucher J, Bronowicki J, Leroy V, Tran A. Efficacy and Safety of an intensified regimen of pegylated interferon alfa-2a plus ribavirin in HCV genotype 1-infected patients who did not respond to a prior standard regimen of pegylated interferon alfa-2a plus ribavirin: an interim analysis of the multicentric, randomized, controlled SYREN trial. Hepatology 2008; 48: 1148A.
  • 47
    Kaiser S, Lutze B, Hass HG. Treatment of peginterferon/ribavirin nonresponders with daily dosingof consensus interferon and ribavirin: results from the german consensus interferon multicenter study. Hepatology 2008; 48: 1143A.